Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-401-0 | CAS number: 106-47-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
Key value for chemical safety assessment
Justification for classification or non-classification
Additional information
The main effect observed after long term exposure to p–chloroaniline is an increase in tumors of the spleen in rats (fibrosarcomas and osteosarcomas) at a high dose of 18 mg/kg. These type of tumours is typical for aniline and related chemicals and is related to the hematotoxic and methemoglobin-forming activity. Repeated exposure to p-chloroaniline leads to cyanosis and methemoglobinemia, and secondary effects occur in blood, liver, spleen, and kidneys and is accompanied by extramedullary hematopoiesis as evidence of a regenerative anemia. Therefore an indirect mechanism is assumed for the tumorigenic activity of p-chloroaniline instead of a genotoxic mode of action.
For the assessment of the human relevance of the spleen tumours observed in rats the following should be considered:
There are physiological differences between rats and humans (information taken from the MAK value documentation for aniline; more details can be found there (http://onlinelibrary.wiley.com/doi/10.1002/3527600418.mb6253e0026b/pdf):
1) Unlike in rats, in which about 5% of erythropoiesis takes place in the spleen throughout the animals lifetime, hematopoiesis stops after birth in the human spleen (as long as the bone marrow function is not impaired)
2) Whereas haematopoiesis takes place in rat spleens via the proliferation of local erythroblasts, in human spleens it takes place via the immigration of erythroid precursors from the blood and subsequent proliferation in the splenic sinus.
3) Under hypoxic conditions, extramedullary haematopoiesis is initially activated in rat spleens, whereas no haematopoiesis is detected in human spleens even if there are anaemic conditions, such as sickle-cell anaemia and thalassaemia.
4) As a result of severe haemolytic anaemia, rat spleens can take on up to 80% of erythropoiesis.
Splenic tumours are extremely rare in humans and splenic tumours have not been reported for human conditions accompanied by methaemoglobinaemia (congenital methaemoglobinaemia), haemolysis (sickle cell anaemia and thalassaemia) or the increased incorporation of iron (haemochromatosis).
Background information on the mechanism for the tumour induction related to methemoglobin forming agents can be found in the MAK value documentation for aniline (http://onlinelibrary.wiley.com/doi/10.1002/3527600418.mb6253e0026b/pdf) as well as in the publications by Nyska et al., Association of liver hemangiosarcoma and secondary iron overload in B6C3F1 mice – the National Toxicology Program experience, Toxicologic Pathology 32, 222-228, 2004 and Cohen et al., Hemansiosarcoma in rodents: Mode-of-Action evaluation and human relevance, Toxicological Sciences 111, 4-18, 2009.
Regarding pheochromocytoma it is known that such tumours occur frequently especially in male rats following a variety of conditions, including hypoxia and the occurrence under such toxic conditions in animal experiments is to be assessed as a secondary effect (Greim et al., Chemically induced pheochromocytomas in rats: mechanisms and relevance for human risk assessment. Critical Reviews in Toxicology 39, 695-718, 2009).
Overall, whereas there is clear evidence of a tumourigenic activity in the (male) rat it can be assumed that the tumour response is related to a secondary mechanisms as a result of the hematotoxic activity. Based in the species differences related to the respective secondary spleen toxicity the spleen tumours observed in the rat after treatment with o-chloroaniline at hematotoxic doses cannot be directly translated to the human situation. Also for the pheochromocytoma a link to hypoxia is to be expected and therefore assessed as a secondary effect. Whereas there is some evidence of a tumourigenic activity in the (male) mouse again there is evidence that the effects observed are secondary to the hematotoxic activity. For both species the effect level for the hematotoxic activity is well below the effect level related to increased tumour incidences.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.